Context Therapeutics, LLC
CNTX US21077P1084
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Lehr Martin A. CEO |
0.70 USD |
100,000 Bought |
70,080 USD |
09/06/2025 | 09/06/2025 |
Lehr Martin A. CEO |
0.70 USD |
100,000 Bought |
70,080 USD |
09/06/2025 | 09/06/2025 |
Minai-azary Jennifer Lynn CFO |
0.64 USD |
40,010 Bought |
25,486 USD |
06/06/2025 | 06/06/2025 |
Levit Alex C. SR OFF |
0.58 USD |
20,000 Bought |
11,520 USD |
06/06/2025 | 06/06/2025 |
Minai-azary Jennifer Lynn CFO |
0.64 USD |
40,010 Bought |
25,486 USD |
06/06/2025 | 06/06/2025 |
Levit Alex C. SR OFF |
0.58 USD |
20,000 Bought |
11,520 USD |
06/06/2025 | 06/06/2025 |